These results establish [18F]GTP1 tau PET as a potential prognostic imaging biomarker in AD and complement prior work from our group demonstrating that [18F]GTP1 tau PET imaging differentiates between AD cohorts of different severity [3] and exhibits significant cross-sectional correlations with cognitive performance [21]. Here, MAPT is linked to Alzheimer disease.